- Title
- Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy
- Creators
- Peter E CLARK - Departments of Urology, Hematology and Oncology, Cancer Biology, and Radiation Oncology, and Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston-Salem, North Carolina, United StatesM. Craig HALL - Departments of Urology, Hematology and Oncology, Cancer Biology, and Radiation Oncology, and Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston-Salem, North Carolina, United StatesFrank M TORTI - Departments of Urology, Hematology and Oncology, Cancer Biology, and Radiation Oncology, and Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston-Salem, North Carolina, United StatesLester S BORDEN - Departments of Urology, Hematology and Oncology, Cancer Biology, and Radiation Oncology, and Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston-Salem, North Carolina, United StatesAntonius A MILLER - Departments of Urology, Hematology and Oncology, Cancer Biology, and Radiation Oncology, and Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston-Salem, North Carolina, United StatesJennifer J HU - Departments of Urology, Hematology and Oncology, Cancer Biology, and Radiation Oncology, and Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston-Salem, North Carolina, United StatesW. Robert LEE - Departments of Urology, Hematology and Oncology, Cancer Biology, and Radiation Oncology, and Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston-Salem, North Carolina, United StatesDiana STINDT - Departments of Urology, Hematology and Oncology, Cancer Biology, and Radiation Oncology, and Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston-Salem, North Carolina, United StatesRalph D'AGOSTINO - Departments of Urology, Hematology and Oncology, Cancer Biology, and Radiation Oncology, and Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston-Salem, North Carolina, United StatesJames LOVATO - Departments of Urology, Hematology and Oncology, Cancer Biology, and Radiation Oncology, and Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston-Salem, North Carolina, United StatesMichelle HARMON - Departments of Urology, Hematology and Oncology, Cancer Biology, and Radiation Oncology, and Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
- Publication Details
- Urology (Ridgewood, N.J.), Vol.67(6), pp.1257-1261
- Publisher
- Elsevier Science; New York, NY
- Academic Unit
- Miller School of Medicine; UMMG Department of Public Health Sciences Research
- Language
- English
- Resource Type
- Journal article
- PMID
- 16765186
- Record Identifier
- 991031559034502976
Journal article
Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy
Urology (Ridgewood, N.J.), Vol.67(6), pp.1257-1261
2006
PMID: 16765186
Metrics
16 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Citation topics
- 3 Agriculture, Environment & Ecology
- 3.171 Photoproductivity
- 3.171.1011 Carotenoids
- Web Of Science research areas
- Urology & Nephrology
- ESI research areas
- Clinical Medicine
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites